Having trouble accessing articles? Reset your cache.

Tysabri natalizumab: Post-marketing study data

Researchers at the University of California, San Francisco, reported data from a retrospective analysis of 84 MS patients who received >=12 infusions of

Read the full 236 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE